Research programme: meningococcal vaccine group B - Sanofi
Alternative Names: Meningococcal group B vaccine; Meningococcal-vaccine-group-B-Emergent-BioSolutonsLatest Information Update: 08 Apr 2022
At a glance
- Originator sanofi pasteur
- Developer Sanofi
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Meningococcal group B infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Meningococcal-group-B-infections in France (Parenteral, Injection)
- 17 Mar 2009 Preclinical development is ongoing with Sanofi Pasteur
- 05 Jun 2006 Preclinical trials in Meningococcal group B infections in France (Parenteral)